Stock ALLO ALLOGENE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Real-time Estimate Cboe BZX
Other stock markets
 03:27:48 2024-05-23 pm EDT 		5-day change 1st Jan Change
2.535 USD -4.70% Intraday chart for Allogene Therapeutics, Inc. -15.45% -20.72%
May. 21 Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating MT
May. 16 HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
GL
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
GL
Allogene Therapeutics: Q1 Earnings Snapshot
AQ
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
GL
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
GL
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
GL
Allogene Therapeutics Announces Q2 Investor Conference Participation
GL
Allogene Therapeutics: Q4 Earnings Snapshot
AQ
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
GL
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
GL
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
GL
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
GL
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
AQ
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
AQ
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
GL
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
GL
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
GL
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
GL
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
AQ
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLO Stock
  4. News Allogene Therapeutics, Inc.
  5. Press Releases